Clinical Trials

376 enrolled 34 charts 1 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01828099 2025-01-16

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Phase 3 Completed

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03546894 2024-07-15

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Completed

111 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Completed

549 enrolled 28 charts

ALK-positive NSCLC

NCT02299505 2022-02-09

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

306 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02450903 2021-03-30

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

20 enrolled 12 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01634763 2020-12-19

Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

22 enrolled

Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

NCT01772797 2020-12-19

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

22 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02292550 2020-12-17

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

27 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01742286 2020-06-09

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

CNSLymphoidPlasma cellSarcoma

83 enrolled 30 charts

Granuloma, Plasma Cell, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Large-Cell, Anaplastic

NCT02336451 2020-04-21

Ascend-7

156 enrolled 39 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT01685138 2019-03-26

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

124 enrolled 18 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01283516 2019-03-15

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

304 enrolled 37 charts

Carcinoma, Non-Small-Cell Lung

NCT02040870 2019-02-20

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Phase 1/2 Completed

103 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT01685060 2017-06-19

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

140 enrolled 17 charts